利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.021 秒)

    IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA
    1.
    发明公开
    IRON(II)-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA 审中-公开
    铁（II）的治疗为高磷血症

    公开(公告)号：EP2043627A2

    公开(公告)日：2009-04-08

    申请号：EP07796408.8

    申请日：2007-06-25

    申请人： GENZYME CORPORATION

    发明人： HUVAL, Chad, C. ,  DHAL, Pradeep, K. ,  HOLMES-FARLEY, Stephen, Randall

    IPC分类号： A61K31/295 ,  A61K33/26 ,  A61K9/14

    CPC分类号： A61K33/26 ,  A61K9/145 ,  A61K9/146 ,  A61K31/295 ,  A61K31/785 ,  A61K45/06 ,  A61K2300/00

    摘要： A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selecte from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.

    AMINE DENDRIMERS
    5.
    发明公开
    AMINE DENDRIMERS 审中-公开
    AMINDENDRIMERE

    公开(公告)号：EP2049014A2

    公开(公告)日：2009-04-22

    申请号：EP07810553.3

    申请日：2007-07-16

    申请人： GENZYME CORPORATION

    发明人： HOLMES-FARLEY, S., Randall ,  DHAL, Pradeep, K. ,  HUVAL, Chad, C.

    IPC分类号： A61B5/055

    CPC分类号： C07C211/14 ,  A61K31/785 ,  A61K47/59 ,  A61K47/595

    摘要： Ion binding compounds and compositions may include compounds, polymers and compositions that include amine moieties. Ion binding polymers may be crosslinked amine polymers and may be used to remove ions, such as phosphate ions, from the gastrointestinal tract of animals, such as humans. Such compounds, polymers and compositions may be used therapeutically to treat a variety of medical conditions, such as hyperphosphatemia.

    SULFONE POLYMER COMPOSITIONS
    6.
    发明公开
    SULFONE POLYMER COMPOSITIONS 审中-公开
    磺化聚合物组合物

    公开(公告)号：EP2131820A1

    公开(公告)日：2009-12-16

    申请号：EP08726435.4

    申请日：2008-03-05

    申请人： Genzyme Corporation

    发明人： DHAL, Pradeep, K. ,  HOLMES-FARLEY, Stephen, Randall ,  HUVAL, Chad, C. ,  POLOMOSCANIK, Steven, C.

    IPC分类号： A61K9/48

    CPC分类号： C08G75/20 ,  C08G65/24 ,  C08G73/0253

    摘要： Sulfone-containing copolymers and copolymer networks and compositions including sulfone-containing copolymers and copolymer networks may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, sulfone-containing copolymers and copolymer networks may be derived from a multi- amine monomer and a multifunctional sulfonyl-containing monomer comprising two or more amine-reactive groups.

    摘要翻译： 含砜共聚物和共聚物网络以及包含含砜共聚物和共聚物网络的组合物可用于结合目标离子，例如动物胃肠道中的含磷化合物。 在一些情况下，含砜共聚物和共聚物网络可以衍生自多胺单体和包含两个或更多个胺反应性基团的多官能磺酰基单体。

    AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS
    8.
    发明公开
    AMINE CONDENSATION POLYMERS AS PHOSPHATE SEQUESTRANTS 审中-公开
    胺缩合聚合物作为磷酸酯序列分子

    公开(公告)号：EP2016114A2

    公开(公告)日：2009-01-21

    申请号：EP07776627.7

    申请日：2007-05-02

    申请人： GENZYME CORPORATION

    发明人： HUVAL, Chad, C. ,  DHAL, Pradeep, K. ,  HOLMES-FARLEY, Stephen, Randall

    IPC分类号： C08G73/02

    CPC分类号： A61K31/785 ,  C08G73/02 ,  C08G73/0206

    摘要： Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a -CH2CH2- group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.

    摘要翻译： 公开了一种聚合物或其生理学上可接受的盐。 该聚合物包含聚合的多官能胺单体。 胺单体包含至少两个胺基和至少两个通过-CH 2 CH 2 - 基连接的无环氮原子，条件是胺单体不是乙二胺或二亚乙基三胺。 所公开的聚合物可以用于结合需要这种治疗的受试者中的阴离子。

    ZINC-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA
    9.
    发明公开
    ZINC-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA 审中-公开
    含锌治疗高磷酸盐血症

    公开(公告)号：EP1830832A1

    公开(公告)日：2007-09-12

    申请号：EP05856055.8

    申请日：2005-12-29

    申请人： GENZYME CORPORATION

    发明人： HUVAL, Chad, C. ,  HOLMES-FARLEY, Stephen, Randall ,  DHAL, Pradeep, K. ,  SYBERTZ, Edmund, J.

    IPC分类号： A61K31/315 ,  A61P3/12

    CPC分类号： A61K31/315 ,  A61K33/30 ,  A61K45/06 ,  A61K2300/00

    摘要： A method of treating hyperphosphatemia in a subject comprises the step of administering to the subject an effective amount of a pharmaceutically acceptable zinc salt. A pharmaceutical composition comprises a pharmaceutically acceptable carrier, a pharmaceutically acceptable zinc salt; and a phosphate sequestrant. In one embodiment, the phosphate sequestrant is selected from a pharmaceutically acceptable lanthanum, calcium, magnesium and iron salt. In another embodiment, the phosphate sequestrant is an amine polymer, wherein the molar ratio of a zinc ion of the ion salt to amine nitrogen atoms in the amine polymer is 0.1-3.0. The invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable carrier; a pharmaceutically acceptable zinc salt; and an agent selected from the group consisting of a phosphate transport inhibitor, and HMG-CoA reductase inhibitor and an alkaline phosphatase inhibitor.

    ARYL BORONIC ACIDS FOR TREATING OBESITY
    10.
    发明授权
    ARYL BORONIC ACIDS FOR TREATING OBESITY 有权
    芳基硼酸用于治疗肥胖

    公开(公告)号：EP1404685B1

    公开(公告)日：2006-09-13

    申请号：EP02746808.1

    申请日：2002-07-01

    申请人： GENZYME CORPORATION

    发明人： HOLMES-FARLEY, Stephen, Randall ,  MANDEVILLE, W., Harry, III ,  HUVAL, Chad, Cori ,  LI, Xinhua ,  DHAL, Pradeep, K.

    IPC分类号： C07F5/02 ,  A61K31/015 ,  A61P3/04

    CPC分类号： C07F5/025 ,  A61K31/74 ,  A61K31/785

    摘要： Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aryl group. Z and Z' are independently -O-. -NH- or -S-. X is an electron withdrawing group. R is a substituted or unsubstituted straight chained hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups and Y is -H, an amine, -[NH-(NH2)q]-NH2, halogen, -CF3, thiol, ammonium, alcohol, -COOH, -SO3H, -OSO3H or phosphonium group covalently bonded to the terminal position of R. Each -NH- in -[NH-)CH2)q]r-NH2 is optionally N-alkylated or N,N-dialkylated and -NH2 in -[NH-(CH2)q]r-NH2 is optionally N-alkylated, N,N-dialkylated or N,N,N-triakylated. q is an integer from 2 to about 10 and r is an integer from 1 to about 5. R1 and R1' are independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or, taken together, are a C2-C5 substituted or unsubstituted alkylene group optionally comprising an amine linking group [-N+(R1a)-]. Each R¿1?, is Structural Formula (I) is preferably -H. R?1a¿ is-H, alkyl, substituted alkyl, phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carier or diluent.